Etiological treatment of chronic Chagas disease: neglected ‘evidence’ by evidence-based medicine

References

• Sackett DH, Busemberg WMC, Gray JAM, Haynes RB, Richardsen WS. Evidence based medicine: what it is and what it isn’t. Br. Med. J.312, 71–72 (1996).
   PubMed Web of Science ®Google Scholar
• Ham C, Hunter C, Robinson R. Evidence based policymaking. Br. Med. J.310, 71–72 (1995).
   PubMed Web of Science ®Google Scholar
• Doval H, Tajer C. Introducción ¿Porqué un libro de cardiología basada en la evidencia. In: Evidencias en Cardiología III “De los ensayos clínicos a las conductas terapéuticas”. GEDIC (Ed.). Buenos Aires, Argentina 35–44 (2003).
   Google Scholar
• Moher D, Schulz K, Altman D; for the Consort Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet357, 1191–1195 (2001).
   PubMed Web of Science ®Google Scholar
• Samaja J. El producto del proceso de investigación. In: Epistemología y Metodología, Parte II. Eudeba (Ed.). Buenos Aires, Argentina 51–142 (1993).
   Google Scholar
• Victora C, Jabicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. Am. J. Public Health94, 400–405 (2004).
   PubMed Web of Science ®Google Scholar
• Des Jarlais D, Lyles C, Crepaz N; and the TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am. J. Public Health94, 361–366 (2004).
   PubMed Web of Science ®Google Scholar
• Ernst E, Canter PH. Limitations of “pragmatic” trials. Postgrad. Med. J.81, 203 (2005).
   PubMed Web of Science ®Google Scholar
• Feldman AM, MacNamara D. Myocarditis. N. Engl. J. Med.343, 1388–1398 (2000).
   PubMed Web of Science ®Google Scholar
• Organización Panamericana de la Salud. Estimación cuantitativa de la enfermedad de Chagas en las Américas, Montevideo, Uruguay: OPS/HDM/CD/425 (2006).
   Google Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation115, 1109–1123 (2007).
   PubMed Web of Science ®Google Scholar
• Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of a T. cruzi DNA sequence of inflammatory lesions in human chagasic cardiomyopathy. Am. J. Trop. Med. Hyg.48, 348–357 (1993).
   PubMed Web of Science ®Google Scholar
• Higuchi M, De Brito T, Reis M et al. Correlation between T. cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc. Pathol.2, 101–116 (1993).
   PubMed Web of Science ®Google Scholar
• Schijman AG, Vigliano CA, Viotti RJ et al.T. cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic Chagas heart disease. Am. J. Trop. Med. Hyg.70, 210–220 (2004).
   PubMed Web of Science ®Google Scholar
• Ouaissi A, Da Silva A, Guevara A, Borges M, Guilvard E. T. cruzi-induced host immune system dysfunction: a rationale for parasite immunosuppressive factor(s) encoding gene targeting. J. Biomed. Biotechnol.1, 111–117 (2001).
   Google Scholar
• Andrade ZA. Immunopathology of Chagas disease. Mem. Inst. Oswaldo Cruz94, 71–80 (1999).
   PubMed Web of Science ®Google Scholar
• Avila H, Pereira J, Thiemann O et al. Detection of T. cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. J. Clin. Microbiol.31, 2421–2426 (1993).
   PubMed Web of Science ®Google Scholar
• Salomone OA, Basquiera AL, Sembaj A et al.T. cruzi in persons without serologic evidence of disease, Argentina. Emerg. Infect. Dis.9, 1558–1562 (2003).
   PubMed Web of Science ®Google Scholar
• Abbas A, Lichtman A, Pober J. Immunity to parasites. Evasion of immune mechanisms by parasites. In: Cellular and Mollecular Immunology, Fourth Edition. W.B. Saunders Company, PA, USA 357–360 (2000).
   Google Scholar
• Elias F, Vigliano C, Laguens R, Levin MJ, Berek C. Analysis of the presence of T. cruzi in the heart tissue of three patients with chronic Chagas’ heart disease. Am. J. Trop. Med. Hyg.68, 242–247 (2003).
   PubMed Web of Science ®Google Scholar
• Koberle F. Cardiopatía chagásica. O Hospital53, 311–346 (1958).
   PubMedGoogle Scholar
• Mott KE, Hagstrom JWC. The pathologic lesions of the cardiac autonomic nervous system in chronic Chagas myocarditis. Circulation31, 273–286 (1965).
   PubMed Web of Science ®Google Scholar
• Spotnitz MD, Lesch M. Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog. Cardiovasc. Dis.49, 42–57 (2006).
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity39, 41–54 (2006).
   PubMed Web of Science ®Google Scholar
• Esteva M, Ruiz A, Cabeza Meckert PM, Cazzulo J, Segura E, Laguens RP. Antigens of the microsomal fraction of T. cruzi produce pathology in mice. J. Protozool.30, 1–14 (1983).
   Google Scholar
• Lopez Bergami P, Cabeza Meckert PM, Kaplan D et al. Immunization with recombinant T. cruzi ribosomal P2β protein induces changes in the electrocardiogram of immunized mice. FEMS Immunol. Med. Microbiol.18, 75–85 (1997).
   PubMedGoogle Scholar
• Laguens RP, Cabeza Meckert PM, Chambo JG, Gelpi R. Chronic Chagas disease in the mouse II. Transfer of the heart disease by means of immunocompetent cells. Medicina41, 40–43 (1981).
   PubMed Web of Science ®Google Scholar
• Hontebeyrie-Joskowicz M, Said G, Milon G, Marcha G, Eisen H. L3T4+ T cells able to mediate parasite-specific delayed-type hypersensitivity play a role in the pathology of experimental Chagas’ disease. Eur. J. Immunol.17, 1027–1033 (1987).
   PubMed Web of Science ®Google Scholar
• Cabeza Meckert PM, Chambó JG, Laguens RP. Presence of cells producing antiheart autoantibodies in the inflammatory infiltrate of chronic chagasic myocarditis. Clin. Immunol. Immunopathol.60, 137–144 (1991).
   PubMedGoogle Scholar
• Laguens RP, Argel MI, Chambo J, Storino R, Cabeza Meckert PM. Presence of antiheart and antiskeletal muscle glycolipid autoantibodies in the sera of patients with chagasic cardiopathy. Can. J. Cardiol.10, 769–776 (1994).
   PubMed Web of Science ®Google Scholar
• Levitus G, Hontebeyrie-Joskowicz M, Vanregenmortel M, Levin MJ. Humoral autoimmune response to ribosomal P-proteins in chronic Chagas heart disease. Clin. Exp. Immunol.85, 413–417 (1991).
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Duranti M, Gruber A et al. Autoimmunity in Chagas’ disease cardiopathy: biological relevance of a cardiac myosin-specific epitope cross-reactive to an immunodominant T. cruzi antigen. Proc. Natl Acad. Sci. USA92, 3541–3545 (1995).
   PubMed Web of Science ®Google Scholar
• Brener Z. Recent advances in the chemotherapy of Chagas disease. Mem. Inst. Oswaldo Cruz79, 149–155 (1984).
   Google Scholar
• Morris SA, Tanowitz HB, Wittner M, Bilezikian JP. Pathophysiological insights into the cardiomyopathy of Chagas’ disease. Circulation82, 1900–1909 (1990).
   PubMed Web of Science ®Google Scholar
• Rossi WA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas’ disease. Am. Heart J.120, 233–236 (1990).
   PubMed Web of Science ®Google Scholar
• Brandariz S, Schijman A, Vigliano C et al. Detection of parasite DNA in Chagas’ heart disease. Lancet346, 1370–1371 (1995).
   PubMedGoogle Scholar
• Vago AR, Macedo AM, Adad SJ, Reis DD, Correa-Oliveira R. PCR detection of T. cruzi DNA in esophageal tissues of patients with chronic digestive Chagas’ disease. Lancet348, 891–892 (1996).
   PubMed Web of Science ®Google Scholar
• Kierszenbaum F. Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends Parasitol.21, 513–516 (2005).
   PubMed Web of Science ®Google Scholar
• Macedo AM, Machado CR, Oliveira RP, Pena SD. T. cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem. Inst. Oswaldo Cruz99, 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Higuchi ML, Benvenuto LA, Reis MM, Metzger M. Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc. Res.60, 96–107 (2003).
   PubMed Web of Science ®Google Scholar
• Tarleton R. Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol.31, 550–554 (2001).
   PubMed Web of Science ®Google Scholar
• Laguens R, Cabeza Meckert P, Vigliano C. Patogenia de la Miocarditis Chagásica Crónica Humana. Medicina59, 63–68 (1999).
   PubMedGoogle Scholar
• Martin D, Tarleton R. Generation, specificity, and function of CD8+ T cells in T. cruzi infection. Immunol. Rev.201, 304–317 (2004).
   PubMed Web of Science ®Google Scholar
• Bellotti G, Bocchi EA, de Moraes AV et al.In vivo detection of T. cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am. Heart J.131, 301–307 (1996).
   PubMed Web of Science ®Google Scholar
• Añez N, Carrasco H, Parada H et al. Myocardial parasite persistence in chronic chagasic patients. Am. J. Trop. Med. Hyg.60, 726–732 (1999).
   PubMed Web of Science ®Google Scholar
• Basquiera AL, Sembaj A, Aguerri AM et al. Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitemia detected by polymerase chain reaction. Heart89, 1186–1190 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas’ disease. J. Infect. Dis.180, 480–486 (1999).
   PubMed Web of Science ®Google Scholar
• Elizari M. La Miocardiopatía Chagásica. Perspectiva histórica. Medicina59, 25–40 (1999).
   PubMed Web of Science ®Google Scholar
• Laranja F, Dias E, Nobrega G, Miranda A. Chagas disease. A clinical, epidemiologic and pathologic study. Circulation14, 1035–1060 (1956).
   PubMed Web of Science ®Google Scholar
• Puigbó J, Giordano H, Suárez C, Acquatella H, Combellas I. Aspectos clínicos en la enfermedad de Chagas. In: Actualizaciones en la Enfermedad de Chagas. Simposio Satélite. Madoery R, Madoery C y Cámera M (Ed.). Organismo oficial del Congreso Nacional de Medicina 27–38 (1993).
   Google Scholar
• Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem. Inst. Oswaldo Cruz94, 317–320 (1999).
   PubMed Web of Science ®Google Scholar
• Maguire J, Hoff R, Sherlock I et al. Cardiac morbidity and mortality due to Chagas disease: prospective electrocardiographic study of a Brazilian community. Circulation75, 1140–1145 (1987).
   PubMed Web of Science ®Google Scholar
• Barret PA, Peter CT, Swan HJ, Singh BN, Mandel WJ. The frequency and prognostic significance of electrocardiographic abnormalities in clinically normal individuals. Prog. Cardiovasc. Dis.23, 299–319 (1981).
   PubMed Web of Science ®Google Scholar
• Carrasco H, Barboza J, Inglessis G, Fuenmayor A, Molina C. Left ventricular cineangiography in Chagas disease: detection of early myocardial damage. Am. Heart. J.104, 595–602 (1982).
   PubMed Web of Science ®Google Scholar
• Acquatella H, Schiller N, Puigbo J et al. M-mode and two dimensional echocardiography in chronic Chagas heart disease: a clinical and pathological study. Circulation62, 787–799 (1980).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Laucella S et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart90, 655–660 (2004).
   PubMed Web of Science ®Google Scholar
• Storino R. Estudios cardiológicos no invasivos. In: Enfermedad de Chagas. Storino R, Milei J, Mosby (Eds). Buenos Aires, Argentina 392–397 (1994).
   Google Scholar
• de Paola A, Gomez J, Terzian A, Miyamoto MH, Martinez Fo EE. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br. Heart J.74, 293–295 (1995).
   PubMedGoogle Scholar
• Viotti R, Vigliano C, Lococo B et al. Exercise stress testing as a predictor of progression of early chronic Chagas heart disease. Heart92, 403–404 (2006).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Salas L, Klein E, Acquatella H et al. Echocardiographic and clinical predictors of mortality in chronic Chagas disease. Echocardiography15, 271–278 (1998).
   PubMed Web of Science ®Google Scholar
• Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation115, 1101–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B et al. Clinical predictors of chronic chagasic myocarditis progression. Rev. Esp. Cardiol.58, 1037–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann. Intern. Med.144, 724–734 (2006).
   PubMed Web of Science ®Google Scholar
• Cançado JR. Tratamento específico. In: Cardiopatía Chagásica. Cançado JR, Chuster M (Eds). Fundaçao Carlos Chagas, Belo Horizonte, Brazil 327–355 (1985).
   Google Scholar
• Cançado JR. Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz94, 331–335 (1999).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas’ disease with benznidazole clinical and serologic evolution of patients with long-term follow-up. Am. Heart J.127, 151–162 (1994).
   PubMed Web of Science ®Google Scholar
• Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA. Reversibility of cardiac fibrosis in mice chronically infected with T. cruzi, under specific chemotherapy. Mem. Inst. Oswaldo Cruz86, 187–200 (1991).
   PubMed Web of Science ®Google Scholar
• Garcia S, Ramos C, Senra J et al. Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrob. Agents Chemother.49, 1521–1528 (2005).
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Presti MS, Rivarola HW et al. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Int. J. Antimicrob. Agents29, 733–737 (2007).
   PubMed Web of Science ®Google Scholar
• Hyland KV, Leon JS, Daniels MD et al. Modulation of autoimmunity by treatment of an infectious disease. Infect. Immun.75(7), 3641–3650 (2007).
   PubMed Web of Science ®Google Scholar
• Fabbro De Suasnabar D, Arias E, Streiger M et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev. Inst. Med. Trop. Sao Paulo42, 99–109 (2000).
   PubMedGoogle Scholar
• Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective–prospective study of antiparasitic therapy. Rev. Fac. Cien. Med. Univ. Nac. Cordoba57, 135–162 (2000).
   PubMedGoogle Scholar
• Viotti R, Vigliano C, Lococo B, Armenti H, Lapuente A, Segura E. Chronic chagasic cardiomyopathy: clinical and serologic evolution with and without benznidazole in long-term follow-up. In: XIII World Congress of Cardiology. Free Papers. Monduzzi (Ed.) 697–701 (1998).
   Google Scholar
• Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo44, 29–37 (2002).
   PubMedGoogle Scholar
• Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am. J. Trop. Med. Hyg.59, 526–529 (1998).
   PubMed Web of Science ®Google Scholar
• de Andrade AL, Zicker F, de Oliveira RM et al. Randomized trial of efficacy of benznidazole in treatment of early T. cruzi infection. Lancet348, 1407–1413 (1996).
   PubMed Web of Science ®Google Scholar
• Francolino S, Fernandez Antunes A, Talice R et al. New evidence of spontaneous cure in human Chagas disease. Rev. Soc. Bras. Med. Trop.36, 103–107 (2003).
   PubMedGoogle Scholar
• Carbalho V, Sousa E, Vila J et al. Heart transplantation in Chagas disease, 10 years after initial experience. Circulation94, 1815–1817 (1996).
   PubMedGoogle Scholar
• Schijman A, Vigliano C, Burgos J et al. Early diagnosis of recurrence of T. cruzi infection by polymerase chain reaction after heart transplantation of a chronic Chagas heart disease patient. Heart Lung Transplant.19, 1114–1117 (2000).
   PubMed Web of Science ®Google Scholar
• Diez M, Favaloro L, Bertolotti A et al. Usefulness of PCR strategies for early diagnosis of Chagas’ disease reactivation and treatment follow-up in heart transplantation. Am. J. Transplant.7, 1633–1640 (2007).
   PubMed Web of Science ®Google Scholar
• Rivera J, Hillis LD, Levine BD. Reactivation of cardiac Chagas disease in acquired immunodeficiency syndrome. Am. J. Cardiol.94, 1102–1103 (2004).
   PubMed Web of Science ®Google Scholar
• Sartori AM, Ibrahim KY, Nunes Westphalen EV et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann. Trop. Med. Parasitol.101, 31–50 (2007).
   PubMed Web of Science ®Google Scholar
• Lambert N, Mehta B, Walters R, Eron JJ. Chagasic encephalitis as the initial manifestation of AIDS. Ann. Intern. Med.144, 941–943 (2006).
   PubMedGoogle Scholar
• Gurtler RE, Segura EL, Cohen JE. Congenital transmission of T. cruzi infection in Argentina. Emerg. Infect. Dis.9, 29–32 (2003).
   PubMed Web of Science ®Google Scholar
• Hermann E, Truyens C, Alonso-Vega C et al. Congenital transmission of T. cruzi is associated with maternal enhanced parasitemia and decreased production of interferon-γ in response to parasite antigens. J. Infect. Dis.189, 1274–1281 (2004).
   PubMed Web of Science ®Google Scholar
• Moraes-Souza H. Chagas infection transmission control: situation of transfusional transmission in Brazil and other countries of Latin America. Mem. Inst. Oswaldo Cruz94, 419–423 (1999).
   PubMed Web of Science ®Google Scholar
• Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, Van der Stuyft P. The validity of serologic tests for T. cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion45, 554–561 (2005).
   PubMed Web of Science ®Google Scholar
• WHO Technical Report Series 905. Control of Chagas disease, Etiological treatment. Geneva, Switzerland (2002).
   Google Scholar
• Jenicek M. Evidence-based medicine: fifteen years later. Golem the good, the bad, the ugly in need of a review? Med. Sci. Monit.12, 241–251 (2006).
   Web of Science ®Google Scholar
• Urbina J, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol.19, 495–501 (2003).
   PubMed Web of Science ®Google Scholar
• Ferraz M, Gazzinelli R, Alves R, Urbina J, Romanha A. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas disease is less dependent on γ interferon than that of Benznidazole. Antimicrob. Agents Chemother.51, 1359–1364 (2007).
   PubMed Web of Science ®Google Scholar